Changes in process and outcome for ST elevation myocardial infarction in central China from 2011 to 2018.
Humans
Female
Middle Aged
ST Elevation Myocardial Infarction
/ drug therapy
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/ therapeutic use
Cross-Sectional Studies
Aspirin
/ therapeutic use
Platelet Aggregation Inhibitors
/ therapeutic use
Adrenergic beta-Antagonists
/ therapeutic use
Hospital Mortality
Registries
Treatment Outcome
Percutaneous Coronary Intervention
Journal
Chinese medical journal
ISSN: 2542-5641
Titre abrégé: Chin Med J (Engl)
Pays: China
ID NLM: 7513795
Informations de publication
Date de publication:
20 Sep 2023
20 Sep 2023
Historique:
received:
31
12
2022
medline:
21
9
2023
pubmed:
7
8
2023
entrez:
7
8
2023
Statut:
ppublish
Résumé
Limited data are available on the changes in the quality of care for ST elevation myocardial infarction (STEMI) during China's health system reform from 2009 to 2020. This study aimed to assess the changes in care processes and outcome for STEMI patients in Henan province of central China between 2011 and 2018. We compared the data from the Henan STEMI survey conducted in 2011-2012 ( n = 1548, a cross-sectional study) and the Henan STEMI registry in 2016-2018 ( n = 4748, a multicenter, prospective observational study). Changes in care processes and in-hospital mortality were determined. Process of care measures included reperfusion therapies, aspirin, P2Y12 antagonists, β-blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and statins. Therapy use was analyzed among patients who were considered ideal candidates for treatment. STEMI patients in 2016-2018 were younger (median age: 63.1 vs . 63.8 years) with a lower proportion of women (24.4% [1156/4748] vs . 28.2% [437/1548]) than in 2011-2012. The composite use rate for guideline-recommended treatments increased significantly from 2011 to 2018 (60.9% [5424/8901] vs . 82.7% [22,439/27,129], P <0.001). The proportion of patients treated by reperfusion within 12 h increased from 44.1% (546/1237) to 78.4% (2698/3440) ( P <0.001) with a prolonged median onset-to-first medical contact time (from 144 min to 210 min, P <0.001). The use of antiplatelet agents, statins, and β-blockers increased significantly. The risk of in-hospital mortality significantly decreased over time (6.1% [95/1548] vs . 4.2% [198/4748], odds ratio [OR]: 0.67, 95% confidence interval [CI]: 0.50-0.88, P = 0.005) after adjustment. Gradual implementation of the guideline-recommended treatments in STEMI patients from 2011 to 2018 has been associated with decreased in-hospital mortality. However, gaps persist between clinical practice and guideline recommendation. Public awareness, reperfusion strategies, and construction of chest pain centers need to be further underscored in central China.
Sections du résumé
BACKGROUND
BACKGROUND
Limited data are available on the changes in the quality of care for ST elevation myocardial infarction (STEMI) during China's health system reform from 2009 to 2020. This study aimed to assess the changes in care processes and outcome for STEMI patients in Henan province of central China between 2011 and 2018.
METHODS
METHODS
We compared the data from the Henan STEMI survey conducted in 2011-2012 ( n = 1548, a cross-sectional study) and the Henan STEMI registry in 2016-2018 ( n = 4748, a multicenter, prospective observational study). Changes in care processes and in-hospital mortality were determined. Process of care measures included reperfusion therapies, aspirin, P2Y12 antagonists, β-blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and statins. Therapy use was analyzed among patients who were considered ideal candidates for treatment.
RESULTS
RESULTS
STEMI patients in 2016-2018 were younger (median age: 63.1 vs . 63.8 years) with a lower proportion of women (24.4% [1156/4748] vs . 28.2% [437/1548]) than in 2011-2012. The composite use rate for guideline-recommended treatments increased significantly from 2011 to 2018 (60.9% [5424/8901] vs . 82.7% [22,439/27,129], P <0.001). The proportion of patients treated by reperfusion within 12 h increased from 44.1% (546/1237) to 78.4% (2698/3440) ( P <0.001) with a prolonged median onset-to-first medical contact time (from 144 min to 210 min, P <0.001). The use of antiplatelet agents, statins, and β-blockers increased significantly. The risk of in-hospital mortality significantly decreased over time (6.1% [95/1548] vs . 4.2% [198/4748], odds ratio [OR]: 0.67, 95% confidence interval [CI]: 0.50-0.88, P = 0.005) after adjustment.
CONCLUSIONS
CONCLUSIONS
Gradual implementation of the guideline-recommended treatments in STEMI patients from 2011 to 2018 has been associated with decreased in-hospital mortality. However, gaps persist between clinical practice and guideline recommendation. Public awareness, reperfusion strategies, and construction of chest pain centers need to be further underscored in central China.
Identifiants
pubmed: 37545028
doi: 10.1097/CM9.0000000000002698
pii: 00029330-202309200-00009
pmc: PMC10508564
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Aspirin
R16CO5Y76E
Platelet Aggregation Inhibitors
0
Adrenergic beta-Antagonists
0
Types de publication
Observational Study
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2203-2209Informations de copyright
Copyright © 2023 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.
Références
GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392: 1736–1788. doi: 10.1016/S0140-6736(18)32203-7.
doi: 10.1016/S0140-6736(18)32203-7
Liu S, Li Y, Zeng X, Wang H, Yin P, Wang L, et al. Burden of cardiovascular diseases in China, 1990-2016: Findings from the 2016 global burden of disease study. JAMA Cardiol 2019; 4: 342–352. doi: 10.1001/jamacardio.2019.0295.
doi: 10.1001/jamacardio.2019.0295
The writing committee of the report on cardiovascular health and diseases in China. Report on cardiovascular health and diseases in China 2019: An updated summary. Chin Circ J 2020;35: 833–854. doi: 10.3969/j.issn.1000-3614.2020.09.001.
doi: 10.3969/j.issn.1000-3614.2020.09.001
Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018;39: 119–177. doi: 10.1093/eurheartj/ehx393.
doi: 10.1093/eurheartj/ehx393
Chinese Society of Cardiology of Chinese Medical Association; Editorial Board of Chinese Journal of Cardiology. [2019 Chinese Society of Cardiology (CSC) guidelines for the diagnosis and management of patients with ST-segment elevation myocardial infarction] (in Chinese). Chin J Cardiol 2019;47: 766–783. doi: 10.3760/cma.j.issn.0253-3758.2019.10.003.
doi: 10.3760/cma.j.issn.0253-3758.2019.10.003
Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation elevation myocardial infarction: An update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. J Am Coll Cardiol 2016; 67: 1235–1250. doi: 10.1016/j.jacc.2015.10.005.
doi: 10.1016/j.jacc.2015.10.005
Li J, Li X, Wang Q, Hu S, Wang Y, Masoudi FA, et al. ST-segment elevation myocardial infarction in China from 2001 to 2011 (The China PEACE-retrospective acute myocardial infarction study): A retrospective analysis of hospital data. Lancet 2015;385: 441–451. doi: 10.1016/S0140-6736(14)60921-1.
doi: 10.1016/S0140-6736(14)60921-1
Chen Z. Launch of the health-care reform plan in China. Lancet 2009;373: 1322–1324. doi: 10.1016/S0140-6736(09)60753-4.
doi: 10.1016/S0140-6736(09)60753-4
Henan Municipal Bureau Statistics; NBS Survey Office in Henan. Henan statistical yearbook 2015. Beijing: China Statistical Press, 2015. Available from: http://oss.henan.gov.cn/sbgt-wztipt/attachment/hntjj/hntj/lib/tjnj/2015/indexch.htm . [Last accessed on 2021 August 31].
Zhang Y, Yu B, Han Y, Wang J, Yang L, Wan Z, et al. Protocol of the China ST-segment elevation myocardial infarction (STEMI) care project (CSCAP): A 10-year project to improve quality of care by building up a regional STEMI care network. BMJ Open 2019;9: e026362. doi: 10.1136/bmjopen-2018-026362.
doi: 10.1136/bmjopen-2018-026362
Kaifoszova Z, Kala P, Alexander T, Zhang Y, Huo Y, Snyders A, et al. Stent for life initiative: Leading example in building STEMI systems of care in emerging countries. EuroIntervention 2014;10(Suppl T): T87–T95. doi: 10.4244/EIJV10STA14.
doi: 10.4244/EIJV10STA14
Liu XY, Zhang Y, Li MW, Wang XP, Qi DD, Hao PY, et al. [Efficacy of thrombolytic therapy using reteplase in cases with acute ST-segment elevation myocardial infarction: Results from a multicenter clinical trial] (in Chinese). Chin J Cardiol 2016;44: 766–770. doi: 10.3760/cma.j.issn.0253-3758.2016.09.007.
doi: 10.3760/cma.j.issn.0253-3758.2016.09.007
Zhang Y, Gao C, Duan G, Liu X, Zhang H, Zhang C, et al. [Survey on the early reperfusion therapy status in patients with ST-segment elevation myocardial infarction hospitalized in tertiary and secondary hospitals in Henan province] (in Chinese). Chin J Cardiol 2015;43: 858–862. doi: 10.3760/cma.j.issn.0253-3758.2015.10.005.
doi: 10.3760/cma.j.issn.0253-3758.2015.10.005
Zhang Y, Wang S, Yang S, Yin S, Cheng Q, Li M, et al. Rationale and design of the Henan ST elevation myocardial infarction (STEMI) registry: A regional STEMI project in predominantly rural central China. BMC Cardiovasc Disord 2019;19: 271. doi: 10.1186/s12872-019-1250-9.
doi: 10.1186/s12872-019-1250-9
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Circulation 2012;126: 2020–2035. doi: 10.1161/CIR.0b013e31826e1058.
doi: 10.1161/CIR.0b013e31826e1058
Peterson ED, DeLong ER, Masoudi FA, O'Brien SM, Peterson PN, Rumsfeld JS, et al. ACCF/AHA 2010 position statement on composite measures for healthcare performance assessment: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (Writing Committee to develop a position statement on composite measures). Circulation 2010;121: 1780–1791. doi: 10.1161/CIR.0b013e3181d2ab98.
doi: 10.1161/CIR.0b013e3181d2ab98
Zhang H, Zheng W, Wu S, Ma JJ, Wang GM, Li Y, et al. Analysis of potential factors contributing to refusal of invasive strategy after ST-segment elevation myocardial infarction in China. Chin Med J 2021;134: 524–531. doi: 10.1097/CM9.0000000000001171.
doi: 10.1097/CM9.0000000000001171
Feng L, Li M, Xie W, Zhang A, Lei L, Li X, et al. Prehospital and in-hospital delays to care and associated factors in patients with STEMI: An observational study in 101 non-PCI hospitals in China. BMJ Open 2019;9: e031918. doi: 10.1136/bmjopen-2019-031918.
doi: 10.1136/bmjopen-2019-031918
Zhong Q, Gao Y, Zheng X, Chen J, Masoudi FA, Lu Y, et al. Geographic variation in process and outcomes of care for patients with acute myocardial infarction in China from 2001 to 2015. JAMA Netw Open 2020;3: e2021182. doi: 10.1001/jamanetworkopen.2020.21182.
doi: 10.1001/jamanetworkopen.2020.21182
Xu H, Yang Y, Wang C, Yang J, Li W, Zhang X, et al. Association of hospital-level differences in care with outcomes among patients with acute ST-segment elevation myocardial infarction in China. JAMA Netw Open 2020;3: e2021677. doi: 10.1001/jamanetworkopen.2020.21677.
doi: 10.1001/jamanetworkopen.2020.21677
Sun P, Li J, Fang W, Su X, Yu B, Wang Y, et al. Effectiveness of chest pain centre accreditation on the management of acute coronary syndrome: A retrospective study using a national database. BMJ Qual Saf 2021;30: 867–875. doi: 10.1136/bmjqs-2020-011491.
doi: 10.1136/bmjqs-2020-011491
Zhang Y, Tian Y, Dong P, Xu Y, Yu B, Li H, et al. Treatment delay and reperfusion management of acute ST-segment elevation myocardial infarction: Analysis of the China STEMI care project phase 1. QJM 2021;114: 299–305. doi: 10.1093/qjmed/hcaa186.
doi: 10.1093/qjmed/hcaa186
Ranasinghe I, Rong Y, Du X, Wang Y, Gao R, Patel A, et al. System barriers to the evidence-based care of acute coronary syndrome patients in China: Qualitative analysis. Circ Cardiovasc Qual Outcomes 2014;7: 209–216. doi: 10.1161/CIRCOUTCOMES.113.000527.
doi: 10.1161/CIRCOUTCOMES.113.000527
Li J, Li X, Ross JS, Wang Q, Wang Y, Desai NR, et al. Fibrinolytic therapy in hospitals without percutaneous coronary intervention capabilities in China from 2001 to 2011: China PEACE-retrospective AMI study. Eur Heart J Acute Cardiovasc Care 2017;6: 232–243. doi: 10.1177/2048872615626656.
doi: 10.1177/2048872615626656
Han YL, Liu JN, Jing QM, Ma YY, Jiang TM, Pu K, et al. The efficacy and safety of pharmacoinvasive therapy with prourokinase for acute ST-segment elevation myocardial infarction patients with expected long percutaneous coronary intervention-related delay. Cardiovasc Ther 2013;31: 285–290. doi: 10.1111/1755-5922.12020.
doi: 10.1111/1755-5922.12020
Pu J, Ding S, Ge H, Han Y, Guo J, Lin R, et al. Efficacy and safety of a pharmaco-invasive strategy with half-dose alteplase versus primary angioplasty in ST-segment-elevation myocardial infarction: EARLY-MYO trial (early routine catheterization after alteplase fibrinolysis versus primary PCI in acute ST-segment-elevation myocardial infarction). Circulation 2017;136: 1462–1473. doi: 10.1161/CIRCULATIONAHA.117.030582.
doi: 10.1161/CIRCULATIONAHA.117.030582
Danchin N, Popovic B, Puymirat E, Goldstein P, Belle L, Cayla G, et al. Five-year outcomes following timely primary percutaneous intervention, late primary percutaneous intervention, or a pharmaco-invasive strategy in ST-segment elevation myocardial infarction: The FAST-MI programme. Eur Heart J 2020;41: 858–866. doi: 10.1093/eurheartj/ehz665.
doi: 10.1093/eurheartj/ehz665
Liu R, Sun YQ, Hou XX, Zheng Y, Huffman MD, Anderson CS, et al. Temporal trends in diagnosis, treatment, and outcome for non-ST-segment elevation acute coronary syndrome in three regions of China, 2008-2015. Chin Med J 2021;134: 1997–1999. doi: 10.1097/CM9.0000000000001664.
doi: 10.1097/CM9.0000000000001664
Peterson ED, Roe MT, Chen AY, Fonarow GC, Lytle BL, Cannon CP, et al. The NCDR ACTION registry-GWTG: Transforming contemporary acute myocardial infarction clinical care. Heart 2010;96: 1798–1802. doi: 10.1136/hrt.2010.200261.
doi: 10.1136/hrt.2010.200261
Puymirat E, Simon T, Cayla G, Cottin Y, Elbaz M, Coste P, et al. Acute myocardial infarction: Changes in patient characteristics, management, and 6-month outcomes over a period of 20 years in the FAST-MI program (French registry of acute ST-elevation or non-ST-elevation myocardial infarction) 1995 to 2015. Circulation 2017;136: 1908–1919. doi: 10.1161/CIRCULATIONAHA.117.030798.
doi: 10.1161/CIRCULATIONAHA.117.030798
Szummer K, Wallentin L, Lindhagen L, Alfredsson J, Erlinge D, Held C, et al. Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: Experiences from the SWEDEHEART registry 1995-2014. Eur Heart J 2017;38: 3056–3065. doi: 10.1093/eurheartj/ehx515.
doi: 10.1093/eurheartj/ehx515